BridgeBio Presents Attruby Data Suggesting Cardiac Reversal in ATTR-CM

What happened

BridgeBio Pharma presented new analyses from the Phase 3 ATTRibute-CM study of its drug Attruby (acoramidis) at the European Society of Cardiology (ESC) Congress 2026. The data, drawn from the open-label extension of the trial, were presented on August 30, 2026.

According to StockTitan, the analyses showed that acoramidis provided cardiac magnetic resonance (CMR)-based evidence of potentially reversing cardiac structural disease, and that patients had more days alive and out of the hospital—specifically, a reported 65 additional days compared to placebo.

BioSpace and Yahoo Finance reported that the presentations included oral and moderated ePoster sessions on long-term improvement and durable survival benefits. The data are from open-label extension analyses, meaning patients who had been on placebo could receive acoramidis after the initial blinded phase.

The company's press release on GlobeNewswire, dated August 26, 2026, also announced the first participant dosed in ASCEND-ATTR, a Phase 3b/4 study evaluating long-term effects of acoramidis on disease regression in ATTR-CM.

Why it matters

ATTR-CM (transthyretin amyloid cardiomyopathy) is a progressive disease where abnormal protein deposits build up in the heart, leading to heart failure. Attruby is one of the few approved treatments and competes with Pfizer's Vyndamax (tafamidis).

These new data, if confirmed, could strengthen Attruby's competitive position by suggesting that the drug may not only stop disease progression but potentially reverse structural changes in the heart—a claim competitors have not made. BioSpace noted the presentations focus on long-term improvement and durable survival benefits.

The company has been building momentum: per a Perplexity finance page, BBIO shares had rallied to near 52-week highs before this presentation. The stock closed at $74.84 on August 29, 2026, down 0.76% from the prior close of $75.41, according to price data.

What this means

This is a medical conference presentation, not an SEC filing. Companies often present trial data at conferences like ESC to share results with cardiologists and investors. The data come from the ATTRibute-CM study, a Phase 3 trial that previously met its primary endpoint.

The open-label extension is a phase where all participants receive the active drug—here, acoramidis—after the initial randomized portion ended. This allows researchers to observe long-term effects beyond the original trial period. The CMR data refer to cardiac magnetic resonance imaging, a technique that measures heart structure and function.

The claim of 'reversal' is based on imaging measures like left ventricular systolic function—how well the heart pumps. StockTitan reported that more days alive and out of hospital is a patient-centered outcome. However, these are complex analyses, and the data are presented by the company; the sources do not provide independent peer-reviewed validation.

While the stock price showed a slight decline on the event date, the overall context is that this is a late-stage drug with approved status (Attruby was approved by the FDA in 2024). The company is also launching ASCEND-ATTR, a study specifically designed to test the hypothesis of disease regression—an acknowledgment that the current data are suggestive but not definitive.

For investors, the key takeaway is that these presentations are part of an ongoing effort to differentiate Attruby in a competitive market. But the data are preliminary and not yet published in a peer-reviewed journal, so they should be interpreted with caution.